LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

Core Insights - LeonaBio has acquired a license for the Phase 3 development of lasofoxifene, a selective estrogen receptor modulator (SERM), which presents a potential multi-billion dollar opportunity for treating breast cancer patients with ESR1 mutations [1][5][3] - The company raised $90 million through private placement financing, with the potential for an additional $146 million from cash-exercisable warrants to support the development of lasofoxifene [1][3] - The Phase 3 clinical trial for lasofoxifene is expected to complete enrollment by Q4 2026, with topline data anticipated in the second half of 2027 [2][5] Clinical Development & Pipeline Programs - Lasofoxifene is designed to target both wild-type and mutant estrogen receptors, particularly for patients with ESR1 mutations who have limited treatment options [4][5] - The ongoing Phase 3 ELAINE-3 trial aims to establish a new standard of care for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, with an amendment to increase the sample size from 500 to 600 participants [5][4] - ATH-1105, another drug candidate, is being developed for ALS and is on track to initiate a Phase 2 proof-of-concept study in the second half of 2026 [2][6] Corporate Updates - The company transitioned from Athira Pharma to LeonaBio, reflecting a strategic evolution towards a more focused and diversified biopharmaceutical entity [3] - Mark F. Kubik was appointed as Chief Business Officer to oversee licensing and corporate development initiatives [6] - The name change aligns with the acquisition of lasofoxifene rights and emphasizes the company's commitment to innovation in treating unmet medical needs [6] Financial Results - As of December 31, 2025, LeonaBio reported cash and cash equivalents of $69.3 million, an increase from $48.4 million in 2024 [17] - Research and development expenses rose to $85.6 million in 2025, primarily due to costs associated with the lasofoxifene license [10][8] - The net loss for 2025 was $105.6 million, or $24.70 per share, compared to a net loss of $96.9 million, or $25.19 per share, in 2024 [14][21]